Celltrion’s Remsima celebrates 10th year of export

Report on the cumulative sales exports of Celltrion’s Remsima over the past decade

Celltrion Health holds a campaign celebrating the 10th anniversary of Remsima’s EU approval

Export performance over 10 years: KRW 5.6 trillion... Joint venture with Remsima SC worth over KRW 6 trillion

Celltrion’s first biosimilar, ‘Remsima’, has marked its 10th anniversary in entering the overseas market.

 

Together with its subcutaneous injection formulation Remsima SC, Remsima successfully settled in the European market and recorded total exports that exceeded KRW 6 trillion over the past 10 years.

 


 Celltrion Healthcare announced on the 11th that it will launch various campaigns throughout the world to celebrate the 10th anniversary of Remsima's approval in Europe.

 

Celltrion Healthcare is Celltrion's affilate that receives antibody biosimilar products from Celltrion and sells them to global distributors.

 


 Celltrion Healthcare plans to hold global lecture tours and symposiums around the globe from year to the second half of next year, starting with the United European Gastroenterology Week.

 

During the campaign, the company will reexamine Remsima's achievements over the past 10 years and identify how the biosimilar industry, which was born with Remsima's success, has been impacting the field.   
 Celltrion received marketing authorization for Remsima in Europe in August 2013 and received the title, ‘the world’s first antibody biosimilar.’ Remsima is a biosimilar of Remicade.

 

Annual exports of Remsima and Remsima SC (Unit: KRW 1 million, Data: FSS)

According to Celltrion Healthcare, Remsima's export volume has gradually increased since it generated exports of KRW 145.3 billion in 2013.

 

Remsima recorded exports of KRW 402.3 billion in 2014, then exceeded KRW 700 billion in 2016.

 


 The growth of Remsima's exports slowed somewhat thereafter, recording exports of KRW 506.9 billion and KRW 401.4 billion in 2017 and 2018, respectively.

 

However, its exports rebounded and exceeded KRW 500 billion for the first time in 2 years in 2019, then continued to grow to exceed KRW 800 billion in 2021 and last year, setting a new record for two consecutive years.

 

By the first half of this year, Remsima recorded exports of KRW 477.3 billion.

 

Remsima's cumulative exports over the past 10 years amounted to KRW 5.6314 trillion.

 


 Remsima SC has also started to produce export results in 2020.

 

Celltrion received approval for Remsima SC, a subcutaneous injection formulation of Remicade, in Europe in November 2019 and began targeting the market in earnest.

 

Remsima SC first generated exports of KRW 34.8 billion in 2020, and then posted KRW 236.9 billion last year, exceeding KRW 1 trillion in exports together with Remsima.

 

Remsima SC recorded exports of KRW 146.6 billion in the first half of this year, exceeding KRW 500 billion in cumulative exports.

 

The cumulative exports of Remsima and Remsima SC together over the past 10 years were calculated to be KRW 6.1394 trillion.

 

Remsima is recording the highest sales performance among finished products sold overseas by domestic pharmaceutical companies.

 


 Celltrion Healthcare explained, “Remsima has steadily maintained its top spot in infliximab prescriptions since surpassing the market share of its original in 2017.” According to the market research institute IQVIA, Remsima recorded a market share of 56% in Europe, including 83% in the UK and 61% in France, in Q1 this year.

 


 An official from Celltrion Healthcare said, “Remsima was able to succeed and maintain its lead in the market for a long time by preoccupying the market after implementing a customized strategy for each country based on proven data on treatment efficacy and safety in the highly competitive biosimilar industry.”